Patents Expiring in May 2032
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | FETZIMA | levomilnacipran hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 204168-001 | Jul 25, 2013 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | ||
| Allergan | FETZIMA | levomilnacipran hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 204168-002 | Jul 25, 2013 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | ||
| Allergan | FETZIMA | levomilnacipran hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 204168-003 | Jul 25, 2013 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | ||
| Allergan | FETZIMA | levomilnacipran hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 204168-004 | Jul 25, 2013 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | ||
| Helsinn Hlthcare | AKYNZEO | fosnetupitant chloride hydrochloride; palonosetron hydrochloride | POWDER;INTRAVENOUS | 210493-001 | Apr 19, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
